<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04275232</url>
  </required_header>
  <id_info>
    <org_study_id>DVB-LC-1</org_study_id>
    <nct_id>NCT04275232</nct_id>
  </id_info>
  <brief_title>Allogenic Plasma Aliquots in the Treatment of Ligneous Conjunctivitis</brief_title>
  <official_title>The Use of Allogenic Plasma Aliquots as a Source of Plasminogen in the Treatment of Ligneous Conjunctivitis, Clinical Trial of One Case</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dorothy Bautista, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Blood Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial University of Newfoundland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allogenic plasma aliquots, used as eye drops, will provide a source of plasminogen in the
      treatment of ligneous conjunctivitis. The investigational product will be available through
      written request from the Sponsor-Investigator to Canadian Blood Services, as approved by
      Health Canada.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ligneous conjunctivitis is a chronic progressive disorder of the conjunctival mucosa which
      occurs secondary to plasminogen deficiency. The condition is characterized by thick, fibrous
      pseudo membranes adherent to the conjunctival surface of the eye lid.The investigational
      product, allogenic plasma aliquots, is a source of plasminogen. It will be used as eye drops,
      to treat recurrences of these pseudo membranes by providing the plasminogen required for
      fibrinolysis. The allogenic plasma aliquots are prepared by Canadian Blood Services. An
      initial supply of 680 vials was made available through the Special Access program, upon
      approval by Health Canada. Through this Clinical Trial, additional allogenic plasma aliquots
      will be available when required to treat recurrences of the pseudo membranes. The study has
      been conditionally approved by local HREB, pending registration with clinicaltrials.gov
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The patient will receive treatment with the interventional biologic product when she experiences recurrences of ligneous conjunctivitis</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resolution of pseudo membrane associated with ligneous conjunctivitis</measure>
    <time_frame>From date of first documented recurrence of pseudo membranes up to two years, starting from the date of enrolment</time_frame>
    <description>Patient to be observed daily to every few weeks for resolution, based on clinical observation</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Ligneous Conjunctivitis, Left Eye</condition>
  <arm_group>
    <arm_group_label>Allogenic Plasma Aliquots</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allogenic Plasma Aliquots to be used as eye drops in the treatment of recurrences of ligneous conjunctivitis. Two drops will be administered to the affected eye, every 1 to 4 hours, depending on severity of the recurrence.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogenic plasma aliquots, a source of plasminogen</intervention_name>
    <description>Plasma eye drops, a source of plasminogen</description>
    <arm_group_label>Allogenic Plasma Aliquots</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject diagnosed with ligneous conjunctivitis associated with Type 1 plasminogen
             deficiency

        Exclusion Criteria:

          -  Subject has concurrent eye disease which prevents use of the investigational drug
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Clinical trial involves one patient (female)</gender_description>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dorothy V Bautista, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial University of Newfoundland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial University of Newfoundland</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Kızılocak H, Ozdemir N, Dikme G, Koç B, Atabek AA, Çokuğraş H, İskeleli G, Dönmez-Demir B, Christiansen NM, Ziegler M, Ozdağ H, Schuster V, Celkan T. Treatment of plasminogen deficiency patients with fresh frozen plasma. Pediatr Blood Cancer. 2018 Feb;65(2). doi: 10.1002/pbc.26779. Epub 2017 Sep 6.</citation>
    <PMID>28876531</PMID>
  </reference>
  <reference>
    <citation>Ku JY, Lichtinger A, Yeung SN, Kim P, Cserti-Gazdewich C, Slomovic AR. Topical fresh frozen plasma and heparin treatment of ligneous conjunctivitis in a Canadian hospital setting. Can J Ophthalmol. 2012 Oct;47(5):e27-8. doi: 10.1016/j.jcjo.2012.03.025. Epub 2012 Jul 13.</citation>
    <PMID>23036559</PMID>
  </reference>
  <reference>
    <citation>Pergantou H, Likaki D, Fotopoulou M, Katsarou O, Xafaki P, Platokouki H. Management of ligneous conjunctivitis in a child with plasminogen deficiency. Eur J Pediatr. 2011 Oct;170(10):1333-6. doi: 10.1007/s00431-011-1483-9. Epub 2011 May 31.</citation>
    <PMID>21625933</PMID>
  </reference>
  <reference>
    <citation>Ang MJ, Papageorgiou KI, Chang SH, Kohn J, Chokron Garneau H, Goldberg RA. Topical Plasminogen as Adjunctive Treatment in Recurrent Ligneous Conjunctivitis. Ophthalmic Plast Reconstr Surg. 2017 Mar/Apr;33(2):e37-e39. doi: 10.1097/IOP.0000000000000694.</citation>
    <PMID>27065432</PMID>
  </reference>
  <reference>
    <citation>Shapiro AD, Nakar C, Parker JM, Albert GR, Moran JE, Thibaudeau K, Thukral N, Hardesty BM, Laurin P, Sandset PM. Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiency. Blood. 2018 Mar 22;131(12):1301-1310. doi: 10.1182/blood-2017-09-806729. Epub 2018 Jan 10.</citation>
    <PMID>29321155</PMID>
  </reference>
  <reference>
    <citation>Conforti FM, Di Felice G, Bernaschi P, Bartuli A, Bianco G, Simonetti A, Buzzonetti L, Valente P, Corsetti T. Novel plasminogen and hyaluronate sodium eye drop formulation for a patient with ligneous conjunctivitis. Am J Health Syst Pharm. 2016 Apr 15;73(8):556-61. doi: 10.2146/ajhp150395.</citation>
    <PMID>27045067</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 7, 2020</study_first_submitted>
  <study_first_submitted_qc>February 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2020</study_first_posted>
  <last_update_submitted>February 16, 2020</last_update_submitted>
  <last_update_submitted_qc>February 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Memorial University of Newfoundland</investigator_affiliation>
    <investigator_full_name>Dorothy Bautista, MD</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Skin Diseases, Genetic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasminogen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

